Drugs in Dev. Endocrinology
Phase II
Denmark 
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TransCon™ hGH Trial Meets Primary Objective in Turner Syndrome At 26 Weeks
Details : Skytrofa (lonapegsomatropin) is a once-weekly growth hormone, is designed to deliver unmodified somatropin. It is being evaluated for the treatment of turner syndrome.
Product Name : Skytrofa
Product Type : Hormone
Upfront Cash : Inapplicable
December 16, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Survodutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 456906 is a dual agonist, acting on glucagon (GCG) receptors and glucagon-like peptide-1 (GLP-1) receptors to regulate energy and glucose homeostasis, and which is expected to improve the metabolic profile of treated individuals.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Survodutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TransCon PTH is a once-daily long-acting prodrug of parathyroid hormone in development for the treatment of adult HP, which is designed to replace PTH at physiologic levels for 24 hours each day to address both the short-term symptoms and long-term compl...
Product Name : TransCon PTH
Product Type : Hormone
Upfront Cash : Inapplicable
October 23, 2020
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study demonstrated that TransCon PTH eliminated standard of care (i.e. off active vitamin D and ≤ 500 mg per day of calcium supplements) in 82 percent of subjects across all dosage arms.
Product Name : TransCon PTH
Product Type : Hormone
Upfront Cash : Inapplicable
October 09, 2020
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Survodutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The long-acting GLP-1/glucagon dual-agonist was concluded to have a favorable safety, tolerability and weight loss profile in Phase 1 clinical testing and it is part of Boehringer Ingelheim’s portfolio in the obesity, NASH and diabetes disease areas.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Survodutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This 26-week, randomised, double-blind, double-dummy, treat-to-target phase 2 clinical trial involved 247 insulin-naïve adults with type 2 diabetes inadequately controlled with metformin with or without a DPP-4i.
Product Name : Awiqli
Product Type : Peptide
Upfront Cash : Inapplicable
June 15, 2020
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PaTH Forward trial met key objectives and showed that TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks.
Product Name : TransCon PTH
Product Type : Hormone
Upfront Cash : Inapplicable
April 20, 2020
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Highlighted data to include 7 abstracts on Rybelsus® and 3 abstracts on investigational, once-weekly insulin icodec.
Product Name : Awiqli
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
